An adenovirus E1A mutant that demonstrates potent and selective systemic anti-tumoral efficacy

Nat Med. 2000 Oct;6(10):1134-9. doi: 10.1038/80474.


Replication-selective oncolytic viruses constitute a rapidly evolving and new treatment platform for cancer. Gene-deleted viruses have been engineered for tumor selectivity, but these gene deletions also reduce the anti-cancer potency of the viruses. We have identified an E1A mutant adenovirus, dl922-947, that replicates in and lyses a broad range of cancer cells with abnormalities in cell-cycle checkpoints. This mutant demonstrated reduced S-phase induction and replication in non-proliferating normal cells, and superior in vivo potency relative to other gene-deleted adenoviruses. In some cancers, its potency was superior to even wild-type adenovirus. Intravenous administration reduced the incidence of metastases in a breast tumor xenograft model. dl922-947 holds promise as a potent, replication-selective virus for the local and systemic treatment of cancer.

Publication types

  • Evaluation Study

MeSH terms

  • Adenoviridae / genetics*
  • Adenovirus E1A Proteins / genetics*
  • Animals
  • Antineoplastic Agents / administration & dosage
  • Antineoplastic Agents / pharmacology*
  • Drug Screening Assays, Antitumor
  • Female
  • Genetic Vectors / administration & dosage
  • Genetic Vectors / pharmacology*
  • Humans
  • Injections, Intralesional
  • Injections, Intravenous
  • Mice
  • Mice, Nude
  • Neoplasm Metastasis / drug therapy
  • Neoplasms / drug therapy
  • Tumor Cells, Cultured
  • Xenograft Model Antitumor Assays


  • Adenovirus E1A Proteins
  • Antineoplastic Agents